Immutep Ltd.’s lead immunotherapy candidate, eftilagimod (IMP-321, efti), plus pembrolizumab reverted previous resistance to PD-1/PD-L1 therapy in part B of the TACTI-002 phase II trial in second-line metastatic non-small-cell lung cancer (NSCLC) in patients refractory to anti-PD-1/PD-L1 therapy.
Shouyao Holdings (Beijing) Co. Ltd. has synthesized DNA-dependent protein kinase (DNA-PK) inhibitors reported to be useful for the treatment of cancer.
Researchers at Dana-Farber Cancer Institute Inc., Memorial Hospital for Cancer and Allied Diseases, Memorial Sloan Kettering Cancer Center and Stevens Institute of Technology have divulged proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding moiety linked to cyclin-dependent kinase 4 (CDK4) and/or 6 (CDK6)-targeting moiety through a linker.
More than a decade ago, three scientists were part of a team at G1 Therapeutics Inc. that led to the now-approved CDK4/6 inhibitor Cosela (trilaciclib). The same work also led to findings showing CDK2 as a promising target for cancers that developed resistance to CDK4/6 inhibition.
Captor Therapeutics SA has offered an update on its lead programs CT-01, CT-02 and CT-05. In the CT-01 program, CPT-6281 is currently undergoing IND/CTA-enabling studies with the first clinical trial expected to start at the end of the year. The first indication will be in hepatocellular carcinoma (HCC).
Breast cancer (BC) is a prevalent form of cancer among women globally. Recent studies suggest that circular RNA (circRNA) plays a significant role in BC progression, but the biological functions and underlying mechanisms remain unexplored. According to a recent study published in the Journal of Translational Medicine, the interaction between circDNAJC11 and TATA-box-binding protein-associated factor 15 (TAF15) promotes BC progression through the upregulation of MAPK6 expression and activation of the MAPK signaling pathway.
Shuttle Pharmaceuticals Holdings Inc. has entered a research agreement with Georgetown University focused on the evaluation of the company's lead histone deacetylase 6 (HDAC6) inhibitor candidate, SP-2-225, evaluating the antitumor effect of the combination of SP-2-225 and radiation therapy in a syngeneic breast cancer model.
A research group at Washington University School of Medicine has released animal data showing restriction of tumor growth with a novel mRNA therapeutic delivered in nanoparticles based on Altamira Therapeutics Ltd.’s Semaphore delivery platform.
The role that mitochondrial inner membrane protein (IMMT) has in regards to clinicopathology and tumor microenvironment in breast cancer in unclear. IMMT is part of the mitochondrial contact site and cristae organizing system (MICOS) and its function is to maintain mitochondrial integrity.
